Financial reports
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
26 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
8-K
Results of Operations and Financial Condition
11 Mar 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
8-K
Other Events
4 Jan 24
8-K
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
8-K
Other Events
12 Sep 23
8-K
Regulation FD Disclosure
24 Aug 23
8-K
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
8 Aug 23
8-K
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
28 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
26 Mar 24
424B5
Prospectus supplement for primary offering
13 Mar 24
424B5
Prospectus supplement for primary offering
11 Mar 24
424B4
Prospectus supplement with pricing info
8 Jan 24
S-3
Shelf registration
29 Dec 23
424B5
Prospectus supplement for primary offering
28 Jun 23
424B5
Prospectus supplement for primary offering
27 Mar 23
S-8
Registration of securities for employees
23 Mar 23
424B5
Prospectus supplement for primary offering
10 Mar 23
S-3
Shelf registration
23 Dec 22
Other
EFFECT
Notice of effectiveness
9 Jan 24
CORRESP
Correspondence with SEC
4 Jan 24
UPLOAD
Letter from SEC
3 Jan 24
EFFECT
Notice of effectiveness
4 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
28 Dec 22
EFFECT
Notice of effectiveness
10 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
UPLOAD
Letter from SEC
24 Oct 22
Ownership
4
Lisa Ricciardi
14 Mar 24
4
John Brendan Doyle
20 Feb 24
4
Anthony Caggiano
20 Feb 24
4
Lisa Ricciardi
20 Feb 24
4
Anthony Caggiano
9 Feb 24
4
Lisa Ricciardi
9 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
PATHSTONE FAMILY OFFICE, LLC
19 Jan 24
SC 13D/A
BIOS Memory SPV I, LP
13 Nov 23
3
Initial statement of insider ownership
13 Nov 23